IQVIA™ Real-World Insights Bibliography

Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from the empagliflozin comparative effectiveness and safety (EMPRISE) study
Author(s): A. Karasik1 , S. Lanzinger2 , E. Chia-Hui Tan3 , D. Yabe4 , D. Jung Kim5 , W. H-H Sheu6 , C. MelzerCohen1 , R.W. Holl2 , K. Ha5 , T. Nyström7 , L. Niskanen8 , M. Linnemann Jensen9 , M.H. Kyaw10, J. Núñez11, EMPRISE EU and East Asia Study Group;
Affiliations(s): Maccabi Research & Innovation Center, Tel Aviv University, Tel Aviv, Israel, 2 Inst. for Epidemiology & Medical Biometry, Uni. of Ulm, Ulm, Germany, 3National Research Inst. of Chinese Medicine, Taipei, Taiwan, 4Dept. of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, Japan, 5Dept. of Endocrinology & Metabolism, Ajou Uni. School of Medicine, Suwon, Republic of Korea, 6Taipei Veterans General Hospital, Taipei, Taiwan, 7Dept. of Clinical Science & Education, Södersjukhuset, Karolinska Institutet, Solna, Sweden, 8Department of Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 9 IQVIA, Copenhagen, Denmark, 10Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, USA, 11Dept. of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain
Publication(s):  https://doi.org/10.2337/DB21-127-LB
Virtual EASD 2021, 57 Annual Meeting, 27 September - 10 October 2021
Document Type(s): Abstract,
Countries: Finland, Germany, Israel, Japan, South Korea, Spain, Sweden, Taiwan,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes,
2021
  L:
A:
English
Database Study, Methodology, Population Based Study,
  Add to report
 
 
Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk ofcardiovascular and renal disease among type 2 diabetes patients in routinecare in europe and israel: EMPRISE study results
Author(s): T Nystroem1;AKarasik2; J Nunez3; S Lanzinger4; C Melzer-Cohen2; R W Holl4;P Casajust5; E Toresson Grip6; M Carrasco7; J Foersch8; K Karlsdotter9;M Tuovinen10; R Klement11;MHKyaw12; L Niskanen
Affiliations(s): Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Solna, Sweden;2Tel Aviv University, Maccabi Research and Innovation Center, Tel Aviv, Israel;3University of Valencia, Department of Cardiology, Hospital Clínico Universitariode Valencia, INCLIVA, CIBER Cardiovascular, Valencia, Spain;4University of Ulm,Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany;5Trial FormSupport, Real-World Evidence, Barcelona, Spain;6Swedish Institute for HealthEconomics Quantify Research, Stockholm, Sweden;7Boehringer Ingelheim EspañaS.A., Barcelona, Spain;8Boehringer Ingelheim Pharma GmbH & Co. Kg, HP CountryMedical Affairs, Ingelheim Am Rhein, Germany;9Boehringer Ingelheim AB, Stock-holm, Sweden;10Boehringer Ingelheim KY, Secondment Boehringer Ingelheim UKHEOR Team, Helsinki, Finland;11IQVIA, Global Database Studies, Tartu, Estonia;12Boehringer Ingelheim Pharmaceutical Inc., Connecticut, United States of America;13University of Eastern Finland, Kuopio, Finland;
Publication(s):  European Journal of Heart Failure (2021)23(Suppl. S2) 2–322doi:10.1002/ejhf.2297
Document Type(s): Abstract, Article,
Countries: Finland, Germany, Israel, Spain, Sweden,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes,
2021
  L:
A:
English
Database Study, Meta analysis, Methodology, Population Based Study,
  Add to report
 
 
Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.
Author(s): Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1.
Affiliations(s): 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden.
Publication(s):  Clinical Epidemiology
Document Type(s): Article,
Countries: Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK,
Click here for the abstract
C:
Y:
Oncology,
2016
  L:
A:
English
Literature Review,
  Add to report